Centralized macro libraries can provide efficient solutions to project programming and analysis needs. They also may provide consistency of statistical methodologies, programming techniques and implementation of industry standards across projects. In the pharmaceutical industry, programming is required to comply with 21 Code of Federal Regulation (CFR) Part 11. This requires traceability of changes to programs or macros. Additionally, validation of programs or macros is needed to ensure they perform the functionality intended. SAS Drug Development (SDD) provides a regulatory compliant repository. This paper addresses the challenges of architecting a centralized macro library stored in SDD for use in analysis and reporting
A new industry standard for clinical trials data, the CDISC Study Data Tabulation Model (SDTM), has ...
The use of programming teams offers both advantages and disadvantages when compared with individual ...
We develop computational and omic-wide methods to identify and validate new biomarkers for personali...
Centralized macro libraries can provide efficient solutions to project programming and analysis need...
Many statisticians and statistical programmers in the pharmaceutical industry will first come to kno...
This paper describes an efficient process that is tailored for the high-volume, batch-based reportin...
Pharmaceutical companies conduct many activities during the statistical analysis of their clinical d...
Defining specific guidelines and standards for designing and developing library macros can significa...
Regulated industries such as pharmaceuticals require specific functionalities of computer systems su...
ABSTRACT A Roadmap showing how SAS code developed outside of the SAS® Drug Development system can be...
Many companies face obstacles in reading flat files due to discrepancies in naming and formatting co...
This paper will demonstrate the stored compiled macro facility in the multi-user clinical data manag...
Adverse events (AE) are commonly reported and analyzed through the use of various summary tables as ...
The CDISC Study Data Tabulation Model (SDTM) is becoming the industry standard for clinical data. Fu...
Within a biostatistics department, it is required that each statistical result reported to the regul...
A new industry standard for clinical trials data, the CDISC Study Data Tabulation Model (SDTM), has ...
The use of programming teams offers both advantages and disadvantages when compared with individual ...
We develop computational and omic-wide methods to identify and validate new biomarkers for personali...
Centralized macro libraries can provide efficient solutions to project programming and analysis need...
Many statisticians and statistical programmers in the pharmaceutical industry will first come to kno...
This paper describes an efficient process that is tailored for the high-volume, batch-based reportin...
Pharmaceutical companies conduct many activities during the statistical analysis of their clinical d...
Defining specific guidelines and standards for designing and developing library macros can significa...
Regulated industries such as pharmaceuticals require specific functionalities of computer systems su...
ABSTRACT A Roadmap showing how SAS code developed outside of the SAS® Drug Development system can be...
Many companies face obstacles in reading flat files due to discrepancies in naming and formatting co...
This paper will demonstrate the stored compiled macro facility in the multi-user clinical data manag...
Adverse events (AE) are commonly reported and analyzed through the use of various summary tables as ...
The CDISC Study Data Tabulation Model (SDTM) is becoming the industry standard for clinical data. Fu...
Within a biostatistics department, it is required that each statistical result reported to the regul...
A new industry standard for clinical trials data, the CDISC Study Data Tabulation Model (SDTM), has ...
The use of programming teams offers both advantages and disadvantages when compared with individual ...
We develop computational and omic-wide methods to identify and validate new biomarkers for personali...